Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Fluorinov Pharma

Fluorinov Pharma
2008 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
$31.7M LATEST DEAL AMOUNT
1 INVESTORS
Description

Operator of a pharmaceutical company intended to develop fluorine-based novel, safer and more effective medicine. The company's services include developing small molecule product portfolio for Multiple Myeloma, Waldenström's Macroglobulinemia, Leukemia, Glioblastoma, Lung and Pancreatic Cancers and Central Nervous System disorders, enabling patients to avail therapeutics to treat and avoid cancer diseases.

Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Other Pharmaceuticals and Biotechnology
Drug Delivery
Primary Office
  • MaRS Centre, South Tower
  • 101 College Street, Suite 300, L-349
  • Toronto, Ontario M5G 1L7
  • Canada
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Fluorinov Pharma’s full profile, request a free trial.

Fluorinov Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 27-Jan-2016 $31.7M 000.00 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2010 Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Fluorinov Pharma Executive Team (2)

Name Title Board
Seat
Contact
Info
Malik Slassi Founder, President & Chief Scientific Officer
Peter Dove Laboratory Manager